Review on sodium glucose co-transporter-2 inhibitors for treatment of type-2 diabetes mellitus
Department of Community Medicine, Jagannath Gupta Institute of Medical Science & Hospital, Budge-Budge, Kolkata, India. 700137.
Review Article
GSC Biological and Pharmaceutical Sciences, 2022, 20(03), 280–292.
Article DOI: 10.30574/gscbps.2022.20.3.0371
Publication history:
Received on 20 August 2022; revised on 24 September 2022; accepted on 26 September 2022
Abstract:
Sodium glucose transporter-2 inhibitors (SGLT2-i) are a class of medicine that have been recently acknowledged and approved for management of Type-2 Diabetes Mellitus (T2DM). They have distinct encouraging extra-pancreatic glucuretic role that has been clinically applied for blood sugar management. Reports have been published for multiple side effects including ketoacidosis & ketonuria induced by SGLT2-i. This endeavor delves into the pharmacokinetics of SGLT-i agents, deliberates the utility of these drugs and suggests steps to maximize the safe use of these agents including their diverse beneficial effects.
Keywords:
Canagliflozin; Dapagliflozin; Empagliflozin; Ketoacidosis; Ketonuria; T2DM
Full text article in PDF:
Copyright information:
Copyright © 2022 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution Liscense 4.0
